TNSN96161A1 - Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant. - Google Patents

Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.

Info

Publication number
TNSN96161A1
TNSN96161A1 TNTNSN96161A TNSN96161A TNSN96161A1 TN SN96161 A1 TNSN96161 A1 TN SN96161A1 TN TNSN96161 A TNTNSN96161 A TN TNSN96161A TN SN96161 A TNSN96161 A TN SN96161A TN SN96161 A1 TNSN96161 A1 TN SN96161A1
Authority
TN
Tunisia
Prior art keywords
preparation
quinoleine
novel
pharmaceutical formulations
formulations containing
Prior art date
Application number
TNTNSN96161A
Other languages
English (en)
Inventor
John Collis Alan
Nathan Abraham Fox David
Newman Julie
Original Assignee
Pfizer Res And Dev Company Nvsa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res And Dev Company Nvsa filed Critical Pfizer Res And Dev Company Nvsa
Publication of TNSN96161A1 publication Critical patent/TNSN96161A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE I ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES FORMULE : DANS LAQUELLE R1 REPRESENTE DIVERS RADICAUX ORGANIQUES, R2 ET R3 REPRESENTENT H OU DIVERS RADICAUX ORGANIQUES, R4 REPRESENTE UN SYSTEME HETEROCYCLIQUE, X REPRESENTE CH OU N, ET L EST ABSENT OU REPRESENTE UN GROUPE CYCLIQUE OU A CHAINE OUVERTE.ELLE CONCERNE EGALEMENT UN PROCEDE POUR LA PREPARATION DE CES COMPOSES. APPLICATION : UTILISATION DE CES COMPOSES DANS UNE FORMULATION PHARMACEUTIQUE POUR LE TRAITEMENT DE L'HYPERPLASIE PROSTATIQUE BENIGNE.
TNTNSN96161A 1995-12-23 1996-12-18 Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant. TNSN96161A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
TNSN96161A1 true TNSN96161A1 (fr) 2005-03-15

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96161A TNSN96161A1 (fr) 1995-12-23 1996-12-18 Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.

Country Status (34)

Country Link
US (3) US6103738A (fr)
EP (1) EP0877734B1 (fr)
JP (1) JP3070958B2 (fr)
KR (1) KR19990076693A (fr)
AP (1) AP715A (fr)
AR (1) AR005166A1 (fr)
AT (1) ATE194598T1 (fr)
AU (1) AU708979B2 (fr)
BG (1) BG102559A (fr)
BR (1) BR9612263A (fr)
CA (1) CA2236814C (fr)
CO (1) CO4480106A1 (fr)
CZ (1) CZ197698A3 (fr)
DE (1) DE69609353T2 (fr)
DK (1) DK0877734T3 (fr)
ES (1) ES2151192T3 (fr)
GB (1) GB9526546D0 (fr)
GR (1) GR3034225T3 (fr)
HN (1) HN1996000082A (fr)
HR (1) HRP960616A2 (fr)
HU (1) HUP9903560A3 (fr)
IS (1) IS4731A (fr)
MA (1) MA26414A1 (fr)
NO (1) NO982913L (fr)
NZ (1) NZ325248A (fr)
OA (1) OA10703A (fr)
PL (1) PL327610A1 (fr)
PT (1) PT877734E (fr)
SK (1) SK81698A3 (fr)
TN (1) TNSN96161A1 (fr)
TR (1) TR199801195T2 (fr)
WO (1) WO1997023462A1 (fr)
YU (1) YU68896A (fr)
ZA (1) ZA9610784B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
CN1308324C (zh) 2000-08-31 2007-04-04 弗·哈夫曼-拉罗切有限公司 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物
JP4031363B2 (ja) * 2001-01-02 2008-01-09 エフ．ホフマン−ラ ロシュ アーゲー α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP2277867B1 (fr) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Composés, compositions pharmaceutiques les contenants et leur utilisation pour traiter le cancer
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
EP1615909B1 (fr) 2003-04-23 2008-07-23 Glaxo Group Limited Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
ME02970B (fr) 2004-06-24 2018-07-20 Vertex Pharma Modulateurs de transporteurs de cassette de liaison a l ́ATP
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
KR20090130051A (ko) 2007-03-14 2009-12-17 엑셀리시스, 인코포레이티드 헤지호그 경로의 억제제
EP2346848B1 (fr) 2008-11-14 2013-02-27 F. Hoffmann-La Roche AG Dérivés de quinazoline comme antagonistes des récepteurs nk3
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
EP2821400B1 (fr) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Procédé pour faire des modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
CA2756376A1 (fr) * 2009-03-23 2010-09-30 Cipla Limited Procede de preparation de la doxazosine et de ses sels
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PL2473487T3 (pl) 2009-09-03 2017-07-31 Bristol-Myers Squibb Company Chinazoliny jako inhibitory kanałów jonowych potasowych
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
JP6251039B2 (ja) 2011-03-11 2017-12-20 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティドＷ．Ｌ． Ｇｏｒｅ ＆ Ａｓｓｏｃｉａｔｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ 固定化された生物学的成分の改良
WO2013043255A1 (fr) * 2011-09-21 2013-03-28 University Of South Alabama Procédés et compositions pour le traitement du cancer des ovaires
WO2013130669A1 (fr) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et son administration
SG11201607973XA (en) 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2018005552A1 (fr) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Composés de quinazoline et d'indole destinés au traitement de troubles médicaux

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy

Also Published As

Publication number Publication date
US6642242B2 (en) 2003-11-04
DK0877734T3 (da) 2000-11-20
AU1371997A (en) 1997-07-17
CZ197698A3 (cs) 1999-03-17
AP9600900A0 (en) 1997-01-31
SK81698A3 (en) 2000-04-10
JP3070958B2 (ja) 2000-07-31
US20030220332A1 (en) 2003-11-27
AU708979B2 (en) 1999-08-19
NO982913L (no) 1998-07-30
HUP9903560A3 (en) 2000-07-28
BG102559A (en) 1999-03-31
CA2236814C (fr) 2001-09-18
AR005166A1 (es) 1999-04-14
NZ325248A (en) 1999-09-29
PT877734E (pt) 2000-12-29
OA10703A (en) 2002-11-28
HUP9903560A2 (hu) 2000-05-28
MA26414A1 (fr) 2004-12-20
EP0877734A1 (fr) 1998-11-18
ES2151192T3 (es) 2000-12-16
HN1996000082A (es) 1997-06-30
CO4480106A1 (es) 1997-07-09
NO982913D0 (no) 1998-06-22
KR19990076693A (ko) 1999-10-15
TR199801195T2 (xx) 1998-10-21
AP715A (en) 1998-12-30
US6103738A (en) 2000-08-15
ATE194598T1 (de) 2000-07-15
JPH11501668A (ja) 1999-02-09
ZA9610784B (en) 1998-06-22
IS4731A (is) 1998-04-29
PL327610A1 (en) 1998-12-21
YU68896A (sh) 1999-07-28
BR9612263A (pt) 1999-07-13
HRP960616A2 (en) 1998-06-30
EP0877734B1 (fr) 2000-07-12
GB9526546D0 (en) 1996-02-28
CA2236814A1 (fr) 1997-07-03
DE69609353T2 (de) 2000-12-07
WO1997023462A1 (fr) 1997-07-03
DE69609353D1 (de) 2000-08-17
US6750214B2 (en) 2004-06-15
US20020049322A1 (en) 2002-04-25
GR3034225T3 (en) 2000-12-29

Similar Documents

Publication Publication Date Title
TNSN96161A1 (fr) Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.
TNSN98004A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2435471A1 (fr) Derives de dihydropyridine, procedes d'obtention et compositions pharmaceutiques en contenant
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
TNSN01082A1 (fr) Derives de thiophene nouveaux, procede pour leur preparation et compositions les contenant
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97015A1 (fr) Nouveaux derives de 19-nor-pregnene.
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
TNSN99205A1 (fr) Macrolides antibiotiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2176668A1 (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
TNSN00250A1 (fr) Composes nouveaux inhibiteurs de pcp, procede pour leur preparation et compositions les contenant